Latest available resultsQuarter ended June 30, 202610-Q · August 4, 2026
Filed with the SECVERTEX PHARMACEUTICALS INC / MA
VRTXPharma & biotech
Next reportNovember 2, 2026Analyst forecast 4.886 $/share
Revenue
$3.33B
▲ +12.5% vs prior year% YoY
Net income
$1.10B
▲ +6.5% vs prior year% YoY
EPS
4.31$
▲ +8.0% vs prior year% YoY
Net margin
33.0%
▼ -1.9 percentage points vs prior year pp YoY
Revenue▲ +12.5 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +6.5 %
EPS▲ +8.0 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $3.33B | |
| Gross profit | $2.84B | 85.3 % |
| Operating income | $1.25B | 37.4 % |
| Net income | $1.10B | 33.0 % |
| R&D | — | |
| EPS (diluted) | 4.31 $ | |
| Balance sheet | ||
| Assets | $27.42B | |
| Liabilities | $7.18B | |
| Equity | $20.25B | |
| Cash | $6.14B | |
| Capital | ||
| Shares outstanding | 253.46M | as of 2026-07-31 |
| Public float | — | |